Drug intelligence / Profile preview

MYO6

Development stage: Preclinical
Lead developer: Myocea
Modality: Small Molecules

Overview

MYO6 is a **preclinical small molecule** drug candidate being developed by **Myocea** for **spinal muscular atrophy**. In the company pipeline, MYO6 is identified as an SMA program targeting **Src** signaling, with the intent of modulating Src-related skeletal muscle and neuromuscular junction biology relevant to disease pathology. No specific chemical identity, binding mode, or detailed pharmacology has been publicly disclosed, so the mechanism is best described as a Src-targeted small molecule discovery program in early development for SMA.

Other names: Myocea-Src-small molecule-Spinal Muscular Atrophy

Targets

SRC (Proto-oncogene tyrosine-protein kinase Src)

Beyond the preview

Go deeper on MYO6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MYO6.

Explore the full profile